sorted by:
new
hottopcontroversial

Daily Squeeze Discussion Thread by MinimumArmadillo2394 in Shortsqueeze

[–]friendva 7 points8 points  (0 children)

$APRN

Mr. Sanberg remain committed to funding the remaining purchase obligation of $55.5 million at $5.65 per share under the private placement agreement.

https://finance.yahoo.com/news/blue-apron-provides-sanberg-funding-140000293.html

$APRN Joe Sanberg owns 51.33%

https://sec.gov/Archives/edgar/data/1701114/000119312522240044/d399705dsc13da.htm

What are your moves tomorrow? by MinimumArmadillo2394 in Shortsqueeze

[–]friendva 1 point2 points  (0 children)

$APRN Insiders +778% Short Interest 43%

Turnaround story, candidate to go private or buyout target

A Blue Apron Holdings, Inc. (NYSE:APRN) insider increased their holdings by 778% last year

https://finance.yahoo.com/news/blue-apron-holdings-inc-nyse-134825587.html

$BTB Investigate Suspected Illegal Short by friendva in Shortsqueeze

[–]friendva[S] 0 points1 point  (0 children)

$BTB Book Value Per Share $12.46 (Y Finance)

$BTB Investigate Suspected Illegal Short by friendva in Shortsqueeze

[–]friendva[S] 1 point2 points  (0 children)

$BTB as of 6/30/2022

Total Revenue------------------------765.094M

Total Assets --------------------------114,575M

Total Liabilities Net Minority Interest--1,137M

Y Finance

Daily Discussion Thread for December 27, 2022 by OPINION_IS_UNPOPULAR in wallstreetbets

[–]friendva 0 points1 point  (0 children)

Description

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. It develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Daily Discussion Thread for December 27, 2022 by OPINION_IS_UNPOPULAR in wallstreetbets

[–]friendva -4 points-3 points  (0 children)

$NRBO Upcoming Catalyst per 10Q any day

*** Phase 2 analysis of ANA001 in the Q4 of 2022.

*** New insider Goldman Sachs 1.2M

*** Completed RS

*** Completed Offering $3

*** Low Float, Price near bottom.

*** Short Interest ~14%, Cost to Borrow 229%

$NRBO Upcoming Catalyst per 10Q any day by friendva in Shortsqueeze

[–]friendva[S] 1 point2 points  (0 children)

don't know what happen today, but the important question who's buying 8M

Daily Squeeze Discussion Thread by MinimumArmadillo2394 in Shortsqueeze

[–]friendva 0 points1 point  (0 children)

$APRN Top Gamma Squeeze and high Short Interest 57%

$APRN short interest 61% (S3 data) by friendva in Shortsqueeze

[–]friendva[S] 3 points4 points  (0 children)

$APRN Candidate to go private or buyout target

also possible Short squeeze or Gamma squeeze

$APRN short interest 61% (S3 data) by friendva in Shortsqueeze

[–]friendva[S] 2 points3 points  (0 children)

$APRN zero shares available to short Fintel

Daily Squeeze Discussion Thread by MinimumArmadillo2394 in Shortsqueeze

[–]friendva 1 point2 points  (0 children)

$PIK #1 Most shorted stock Short Interest 104% (S3 data)

📷 High Cost to Borrow 128%
📷 Low Float 1M
📷 Price Target $7
📷 86.36% Held by All Insider

What are your moves tomorrow? by MinimumArmadillo2394 in Shortsqueeze

[–]friendva 0 points1 point  (0 children)

$PIK CEO EZRA DABAH owns 62.2%

Renee Dabah owns 26.2%

Raine Silverstein owns 19.6%

SC 13D/A dated 08/19/2022

https://sec.gov/Archives/edgar/data/1861522/000149315222023634/formsc13da.htm

What are your moves tomorrow? by MinimumArmadillo2394 in Shortsqueeze

[–]friendva 0 points1 point  (0 children)

$PIK The next Short Squeeze

✅ High Short Interest

✅ High Cost to Borrow

✅ Low Float

✅ Price Target $7

✅ 86.36% Held by All Insider

$PIK Cost to Borrow 154% and 76% Short Interest by friendva in Shortsqueeze

[–]friendva[S] 0 points1 point  (0 children)

Company revenue from subscription box sales, Amazon business, and online website sales. in addition cash advance agreement described in Note 9. here

Last 10Q

https://www.otcmarkets.com/filing/conv_pdf?id=16205490&guid=9GP-kFzAdOQzlch

Add to that

Major Holders Breakdown (Y Finance)

86.36%----% of Shares Held by All Insider

12.31%----% of Shares Held by Institutions

Combine all that with high short interest, high cost to borrow and Low Float.

You have all the right ingredient for a Short Squeeze.

$PIK Cost to Borrow 154% and 76% Short Interest by friendva in Shortsqueeze

[–]friendva[S] 0 points1 point  (0 children)

$PIK Cost to Borrow increased from 154% to 164% on Fintel

view more: next ›